Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa In The News.
Press releases published on September 25, 2025
Newsmatics to Showcase the Evolution of Press Releases for Boosting AI Reach at MarCom Summit
Company executives will demonstrate how an effective press release can boost a brand’s visibility in AI platforms WASHINGTON , DC, UNITED STATES, September 25, 2025 /EINPresswire.com/ -- Getting your press releases in front of journalists is valuable, …
Denebola Technologies Secures Strategic Investment to Scale Healthcare for 10 Million Women in Uganda
Denebola: Unlocking Health, Unlocking Futures for Africa's Women KAMPALA, CENTRAL, UGANDA, September 25, 2025 /EINPresswire.com/ -- Denebola Technologies, a Ugandan social enterprise, today announced a significant strategic investment from the Women …
Paramount Gold Nevada Provides Details of Its Upcoming AGM
WINNEMUCCA, Nev., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that its Annual General Meeting (“AGM” or the “meeting”) of the stockholders will be held on …
European Travel Secures Triple International Award Nominations for 2025
European Travel honored with three global award nominations, showcasing excellence in corporate travel across Africa and beyond. BAMAKO, BAMAKO, MALI, September 25, 2025 /EINPresswire.com/ -- European Travel, a corporate travel solutions provider, has …
Aya Gold & Silver Categorically Rejects the Erroneous and Misleading Allegations Made Against the Company
MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) strongly refutes the misleading and inaccurate claims contained in the short-seller report. The report contains numerous inaccuracies …
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in …
Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting …
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant …
Mejora la liquidez en más de un 185 % en los contratos de derivados de BitMEX tras la migración estratégica a AWS Tokio
VICTORIA, Seychelles, Sept. 25, 2025 (GLOBE NEWSWIRE) -- BitMEX, una de las bolsas de criptomonedas más seguras del mundo, anunció hoy el impacto transformador del éxito de la migración de su motor de negociación a AWS Tokio. Esta medida ha supuesto una …
AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得
この特許は、ライセンス供与、共同研究、長期的な収益成長の機会を提供し、国際市場での保護拡大を目指すAIMの戦略を支えるものである 日本は世界第3位の医薬品市場であり、がん領域は最も成長が速い治療分野である フロリダ州オカラ発, Sept. 26, 2025 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE American: AIM) (「AIM」または「同社」) は本日、日本特許庁が同社独自のアンプリジェン (Ampligen®) …
Global Helium Corp. Confirms Mailing of Circular for Upcoming Meeting of Shareholders for Plan of Arrangement
CALGARY, Alberta, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Global Helium Corp. (“Global” or the “Company”) (CSE: HECO) and 2679158 Alberta Ltd. (the “Purchaser”) announce that, further to the press release dated July 16, 2025, the Company has confirmed that …
NexGold Announces US$24 Million Royalty and Non-Binding LOI for up to US$175 Million in Project Financing for the Advancement of the Goldboro Gold Project
Highlights: US$24 million financing through the sale of a Royalty to Appian Capital Advisory Limited, supporting the advancement of the Goldboro Gold Project in Nova Scotia. Summary details of the Royalty include: US$24 million upfront payment in cash; 2. …
Blue Moon Metals Announces Upsize of Bought Deal Public Offering to C$75 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Blue Moon Metals Inc. ("Blue Moon" or the "Company") (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that as a …
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing …
Over 185% Liquidity Improvements on BitMEX Derivatives Contracts Following Strategic AWS Tokyo Migration
VICTORIA, Seychelles, Sept. 25, 2025 (GLOBE NEWSWIRE) -- BitMEX, one of the world’s safest crypto exchanges, today announced the transformative impact of its successful trading engine migration to AWS Tokyo. The move has delivered liquidity improvements by …
ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Offers High-Margin Operating Model, Defined Path to Production
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN ( …
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Sites …
ORYZON to Participate in Upcoming Events in September and October
MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at …
Pan American Energy Announces Details of Upcoming Tharsis Field Program
CALGARY, Alberta, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTC: PAANF | FRA: SS6) (“Pan American” or the “Company”) is pleased to provide further details of the upcoming 2025 exploration campaign at the Tharsis Project, …